Press Releases

10.28.2019
Iveric Bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
09.30.2019
Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
09.30.2019
CORRECTING and REPLACING Iveric Bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference
09.17.2019
Iveric Bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
09.04.2019
Iveric Bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019
08.07.2019
Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference
08.01.2019
Iveric Bio Reports Second Quarter 2019 Financial and Operating Results
07.25.2019
Iveric Bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
07.23.2019
Iveric Bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program
06.17.2019
Iveric Bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases